Table 2.

Immunotherapy related to lipid metabolism for cancers

Targets	Agents	Mechanisms	Developments
CPT1A	Etomoxir	Inhibition of FAO	Preclinical
CTLA‐4	Ipilimumab	Checkpoint blockade; inhibition of FAO	FDA‐Approved
PD‐1/PD‐L1	Nivolumab, Pembrolizumab, Atezolizumab 2	Checkpoint blockade; inhibition of FAO	FDA‐Approved
AMPK	Metformin	Increased FAO	FDA‐Approved

Abbreviations: AMPK, adenosine monophosphate‐activated kinase; CPT1A, carnitine palmitoyltransferase 1‐a; CTLA‐4, cytotoxic T lymphocyte antigen 4; FAO, fatty acid β‐oxidation; PD‐1, programmed cell death‐1.